All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
LONDON – Bridgebio Inc. has made a huge turn on the initial $65 million it invested in 2018 to acquire rights to infigratinib from Novartis AG, sealing a $2 billion commercialization deal with Swiss oncology specialist Helsinn Group for the fibroblast growth factor receptor (FGFR) inhibitor just four years later. Helsinn will work with Bridgebio affiliate QED Therapeutics Inc. on U.S. co-commercialization of infigratinib in oncology and all other indications apart from skeletal dysplasias, with profits and losses shared on a 50-50 basis.